Evotec SE (NASDAQ:EVO - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $4.16, but opened at $4.32. Evotec shares last traded at $4.29, with a volume of 6,705 shares changing hands.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on the stock. Jefferies Financial Group lowered shares of Evotec from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $8.70 to $3.80 in a report on Monday, October 7th. HC Wainwright reissued a "buy" rating and set a $8.00 price target on shares of Evotec in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $5.93.
Check Out Our Latest Stock Analysis on Evotec
Evotec Price Performance
The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average of $4.55 and a 200 day moving average of $4.13.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in EVO. Vanguard Personalized Indexing Management LLC bought a new position in Evotec during the 2nd quarter worth approximately $87,000. DCF Advisers LLC raised its holdings in Evotec by 140.5% in the second quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock worth $552,000 after purchasing an additional 67,156 shares during the period. Novo Holdings A S bought a new position in shares of Evotec during the second quarter worth $71,183,000. Mediolanum International Funds Ltd acquired a new position in shares of Evotec in the 3rd quarter valued at $512,000. Finally, Clear Harbor Asset Management LLC bought a new stake in shares of Evotec in the 3rd quarter valued at $104,000. Institutional investors and hedge funds own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
See Also
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
